Creative Medical Technology announces 1-for-10 reverse stock split effective June 12, 2023 to regain Nasdaq compliance

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

Reverse split ratio 1-for-10; outstanding shares reduced from ~14.1M to ~1.4M.
Authorized shares cut from 50M to 5M; no change to par value of $0.001.
Effective 9:00 a.m. ET on June 12, 2023 under ticker CELZ; new CUSIP 22529Y408.
Fractional shares rounded up to whole share; no cash paid in lieu.
Action intended to bring stock above $1.00 minimum bid price for Nasdaq listing.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.: Reverse stock split at 1-for-10 ratio and reduction of authorized common stock from 50 million to 5 million via Certificate of Change filed with Nevada Secretary of State (effective 2023-06-12).

Change: charter amendment
Effective: 2023-06-12

Exact text from the filing

Following the approval of the Board of Directors of Creative Medical Technology Holdings, Inc., a Nevada corporation (the “Company”), the Company is effecting a reverse stock split of its common stock, par value $0.001 per share (the “Common Stock”), at a ratio of 1-for-10 (the “Reverse Stock Split”). The Reverse Stock Split will be effected pursuant to a Certificate of Change Pursuant to NRS 78.209 (the “Certificate”) that was filed with the Secretary of State of the State of Nevada on June 1, 2023. In addition to effecting the Reverse Stock Split, the filing of the Certificate reduces the authorized number of shares of the Company’s Common Stock from 50 million to five million.

View on SEC.gov

Browse all governance changes →

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001477932-23-004441

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.